Cas No.: | 2089415-51-8 |
Chemical Name: | PQM130 |
Synonyms: | PQM130 |
SMILES: | C(OCC1CCN(CC2=CC=CC=C2)CC1)(=O)/C=C/C1=CC=C(O)C(OC)=C1 |
Formula: | C23H27NO4 |
M.Wt: | 381.46 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO |
Description: | PQM130, a Feruloyl-Donepezil Hybrid compound with brain penatration, is a multitarget drug candidate against the neurotoxicity induced by Aβ1-42 oligomer (AβO) and shows anti-inflammatory activity. PQM130 acts as a neuroprotective compound for anti-AD drug development[1]. |
In Vivo: | PQM130 (0.5-1 mg/kg, i.p., daily for 10 days) treatment after the i.c.v. AβO injection reduces oxidative damage and neuroinflammation and induces cell survival and protein synthesis through the modulation of GSK3β and extracellular signal-regulated kinases (ERK1/2) [1]. Animal Model: Adult male C57Bl/6 mice (9 weeks old, 25-30 g body weight) [1]. Dosage: 0.5 and 1.0 mg/kg. Administration: IP injection daily for 10 days. Result: Ameliorated Aβ1-42O-induced cognitive deficits in mice. Prevented Aβ1-42O-induced neuronal death in mice. Antagonized Aβ1-42O-Induced Oxidative Stress in Mice. Regulated GSK3β and ERK1/2 protein expressions in mice. Reduced Aβ1-42O-induced astrocytic activation in mice. |
References: | [1]. Morroni F, et al. PQM130, a Novel Feruloyl-Donepezil Hybrid Compound, Effectively Ameliorates the Cognitive Impairments and Pathology in a Mouse Model of Alzheimer's Disease. Front Pharmacol. 2019 Jun 12;10:658. |